Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-29DOI: 10.1080/17410541.2026.2754363
Reza Khedri, Mandana Pouladzadeh, Meisam Moezzi, Mohammad Reza Mahmoudian-Sani
{"title":"Circulating miR-223 and NLRP3 expression and their discriminatory performance in acute ischemic stroke.","authors":"Reza Khedri, Mandana Pouladzadeh, Meisam Moezzi, Mohammad Reza Mahmoudian-Sani","doi":"10.1080/17410541.2026.2754363","DOIUrl":"10.1080/17410541.2026.2754363","url":null,"abstract":"<p><strong>Introduction: </strong>Acute ischemic stroke (AIS) is a major cause of mortality and disability. Inflammation contributes to ischemic brain injury, and circulating miR-223 and NLRP3 may reflect inflammatory responses. This study evaluated their expression and diagnostic performance in AIS.</p><p><strong>Methods: </strong>In this case-control study, serum samples were obtained from 45 patients with AIS and 45 healthy controls. Patient blood samples were collected within 24 hours of hospitalization. miR-223 and NLRP3 expression were quantified by quantitative real-time PCR. Spearman correlation, ROC analysis, and multivariable logistic regression were performed.</p><p><strong>Results: </strong>Circulating miR-223 and NLRP3 expression levels were significantly higher in AIS than in healthy controls (both <i>p</i> < 0.0001). ROC analysis showed AUCs of 0.9704 for NLRP3 and 0.8953 for miR-223. In multivariable logistic regression including age, gender, creatinine, miR-223, and NLRP3, NLRP3 was independently associated with AIS (adjusted OR = 0.569, 95% CI: 0.394-0.822, <i>p</i> = 0.003), whereas miR-223 was not (adjusted OR = 0.943, 95% CI: 0.638-1.395, <i>p</i> = 0.769). Age, gender, and creatinine were not independently associated with AIS.</p><p><strong>Conclusion: </strong>miR-223 and NLRP3 showed significant differences and discriminatory performance in AIS. NLRP3 was independently associated with AIS, whereas miR-223 was not. Prospective validation is needed.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"465-473"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-11-01DOI: 10.1080/17410541.2026.2753750
Jürgen Deckert, Heike Weber, Maike Scherf-Clavel, Chantal Hampf, Angelika Erhardt-Lehmann
{"title":"Epigenetics and the personalized treatment of anxiety disorders.","authors":"Jürgen Deckert, Heike Weber, Maike Scherf-Clavel, Chantal Hampf, Angelika Erhardt-Lehmann","doi":"10.1080/17410541.2026.2753750","DOIUrl":"10.1080/17410541.2026.2753750","url":null,"abstract":"<p><p>Anxiety disorders are to be treated with cognitive behavioral therapy and serotonergic antidepressants. Clinical aspects are to be taken into account in an individualized approach. To further develop personalized, biomarker-based treatments neuroscience research has focused on brain imaging, laboratory markers, genetics and epigenetics. The current review focuses on research on how epigenetic variation affects therapy outcome. It summarizes the literature which comprises 12 studies focusing on the role of DNA methylation with few replicated findings between studies. Results are summarized and interpreted in context with genetic findings. Methodological limitations of epigenetic studies are discussed. First, cohort sizes are small compared to those used in genetic studies. Second, preanalytical procedures are of particular importance in epigenetic research because of the inherent instability of DNA methylation; generally accepted standard protocols are currently lacking. Third, the transferability of blood methylation status to brain or liver has to be addressed in interpretation of the results. Solutions to address these methodological challenges are discussed focusing on a synergistic approach with genetic studies. The development of a consensus on standards of epigenetic methodology will be essential to allow the realization of its potential for a personalized treatment of anxiety disorders.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"475-485"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149329242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-11-06DOI: 10.1080/17410541.2026.2754353
Nuray Bayar Muluk
{"title":"The role of tezepelumab in treatment of chronic rhinosinusitis with nasal polyps.","authors":"Nuray Bayar Muluk","doi":"10.1080/17410541.2026.2754353","DOIUrl":"10.1080/17410541.2026.2754353","url":null,"abstract":"<p><strong>Objectives: </strong>This paper aims to comprehensively review the therapeutic role and clinical efficacy of tezepelumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP).</p><p><strong>Methods: </strong>A narrative literature review was conducted (databases searched: PubMed/Medline, Scopus, Web of Science, and Embase; inclusive dates: from inception to early 2024). The search strategy employed keywords including tezepelumab, thymic stromal lymphopoietin (TSLP), CRSwNP, and biologics.</p><p><strong>Results: </strong>Tezepelumab is a fully human IgG2λ monoclonal antibody that neutralizes TSLP by preventing receptor binding. It is one of four respiratory biologics currently approved for managing CRSwNP in Europe and the US. TSLP is a crucial upstream cytokine that induces Type 2 inflammation and is found in high concentrations within nasal polyp tissues. By blocking TSLP, tezepelumab disrupts this inflammatory cascade. Clinical evidence demonstrates that its administration significantly reduces nasal polyp dimensions and substantially alleviates sinonasal symptoms and congestion.</p><p><strong>Conclusion: </strong>Targeted biologic therapies represent a monumental advancement in clinical medicine, fundamentally improving patients' quality of life. Because TSLP drives inflammatory pathways extending beyond classic T2-high disease profiles, tezepelumab offers distinct therapeutic advantages. It is particularly beneficial for severe, uncontrolled asthmatics with comorbid CRSwNP, delivering clinically significant enhancements in overall sinonasal symptomatology.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"519-527"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-23DOI: 10.1080/17410541.2026.2753744
Nuray Bayar Muluk
{"title":"Artificial intelligence in modern medicine: a comprehensive review of technologies, applications, and future directions.","authors":"Nuray Bayar Muluk","doi":"10.1080/17410541.2026.2753744","DOIUrl":"10.1080/17410541.2026.2753744","url":null,"abstract":"<p><strong>Objectives: </strong>We evaluated the transformative impact of AI modalities on clinical practice, distinguishing between retrospective algorithmic performance and prospective clinical effectiveness.</p><p><strong>Methods: </strong>Comprehensive searches were executed [databases searched: January 2016 to October 2024] across PubMed/Medline, Scopus, and Web of Science, identifying peer-reviewed original research and clinical trials. Non-peer-reviewed materials and commercial web sources were strictly excluded.</p><p><strong>Results: </strong>AI technologies-particularly deep learning (DL), natural language processing (NLP), and foundation models-demonstrate high diagnostic accuracy in retrospective cohorts across radiology, dermatology, and pathology. In precision therapeutics, AI accelerates drug discovery and facilitates multi-omics integration for individualized treatment planning. Furthermore, autonomous AI systems have proven cost-effective in nationwide diabetic retinopathy screening programs. However, significant gaps remain between in-silico success and real-world clinical utility. Primary barriers include the lack of prospective randomized trials, pervasive risks of algorithmic bias threatening health equity, the \"black box\" nature of deep neural networks, and stringent interoperability challenges.</p><p><strong>Conclusion: </strong>AI serves as a potent computational catalyst for advancing personalized medicine. To transition from retrospective experimental success to standard-of-care clinical integration, future research endeavors must prioritize Explainable AI (XAI), federated learning frameworks for privacy preservation, and rigorous prospective clinical validation under standardized regulatory oversight.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"513-518"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149279176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-28DOI: 10.1080/17410541.2026.2753761
Aliya Abbas Rizvi, Mohammad Abbas, Tabrez Faruqui, Asma Imran Ansari, Zeba Siddiqi, Sushma Verma, Farzana Mahdi
{"title":"Clinical and computational exploration of <i>IRS1</i> and Pancreastatin genetic variants in metabolic response to metformin-sulfonylurea therapy.","authors":"Aliya Abbas Rizvi, Mohammad Abbas, Tabrez Faruqui, Asma Imran Ansari, Zeba Siddiqi, Sushma Verma, Farzana Mahdi","doi":"10.1080/17410541.2026.2753761","DOIUrl":"10.1080/17410541.2026.2753761","url":null,"abstract":"<p><strong>Background: </strong>Individuals with type 2 diabetes mellitus (T2DM) show variable responses to metformin-sulfonylurea therapy. Genetic variation in insulin signaling and metabolic regulation, particularly in insulin receptor substrate-1 (IRS1) and pancreastatin (PST), may contribute to this variability. This study assessed the influence of <i>IRS1</i> (rs1801278) and <i>PST</i> (rs9658664) polymorphisms on baseline metabolic profiles and response to combination therapy.</p><p><strong>Methods: </strong>We enrolled 202 diabetic individuals receiving metformin-sulfonylurea therapy. Clinical and biochemical parameters were measured at baseline and follow-up. Genotyping for <i>IRS1</i> (rs1801278) and <i>PST</i> (rs9658664) was performed using PCR-RFLP and statistically analyzed by SPSS (v.27). Exploratory molecular docking analyses were performed to examine mutation-dependent differences in PST interactions with insulin-signaling proteins.</p><p><strong>Results: </strong>Renal complications were more prevalent among non-responders (<i>p</i> = 0.029). <i>IRS1</i> and <i>PST</i> genotypes were not associated with therapeutic response. Individuals with IRS1 TT genotype exhibited higher baseline cholesterol, triglyceride, and LDL levels (<i>p</i> = 0.05). Docking analyses suggested mutation-dependent differences in PST interactions with insulin receptor, IRS1, and GRP78. Metformin showed slightly stronger predicted binding to insulin receptor and IRS1 than sulfonylurea.</p><p><strong>Conclusion: </strong>Although <i>IRS1</i> and <i>PST</i> polymorphisms did not show association with treatment response, genotype-based metabolic variability and in silico analyses suggest functional effects on insulin-signaling pathways, highlighting the potential of personalized medicine approaches for optimizing antidiabetic therapy.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"453-464"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-30DOI: 10.1080/17410541.2026.2753779
Tao Ying, Liao Zhangxiu, Wei Jiankai
{"title":"Association of VISTA and BTLA polymorphisms with the risk of non-HBV and non-HCV related hepatocellular carcinoma in Western Guangxi, China: a pilot case-control study.","authors":"Tao Ying, Liao Zhangxiu, Wei Jiankai","doi":"10.1080/17410541.2026.2753779","DOIUrl":"10.1080/17410541.2026.2753779","url":null,"abstract":"<p><strong>Introduction: </strong>Immune checkpoint including VISTA (V-domain Ig suppressor of T cell activation) and BTLA (B and T lymphocyte attenuator) critically regulate tumor immune evasion, and their genetic polymorphisms correlate multiple malignancies. With HBV vaccination and antiviral therapy advancing, non-B non-C hepatocellular carcinoma (NBNC-HCC) prevalence rises, while reliable early diagnosis biomarkers for NBNC-HCC remain lacking.</p><p><strong>Aim: </strong>Thus, the present study investigates the associations between VISTA and BTLA polymorphisms and the risk of NBNC-HCC in western Guangxi, China, so as to facilitate targeted high-risk population screening for NBNC-HCC.</p><p><strong>Methods: </strong>A total of 125 NBNC-HCC patients and 150 healthy individuals were enrolled. Genotyping of VISTA (rs748113, rs10762477, rs3747862) and BTLA (rs3112270, rs1982809, rs1844089) was performed using multiplex PCR combined with targeted sequencing.</p><p><strong>Results: </strong>The AG vs AA, AG-GG vs AA, and allele G vs A of VISTA rs3747862, as well as the AA vs GG, GA-AA vs GG, AA vs GA-GG, and allele A vs G of BTLA rs1844089, were all associated with a significantly increased risk of NBNC-HCC (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Given the relatively limited sample size and low statistical power, the observed associations between VISTA and BTLA polymorphisms and the risk of NBNC-HCC should be considered hypothesis-generating and require further systematic validation.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"439-451"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-30DOI: 10.1080/17410541.2026.2754362
Gerasimia D Kyrochristou, Ilektra D Kyrochristou, Aikaterini Papameti, Fotios S Fousekis, Stefano Rausei, Konstantinos Vlachos, Georgios D Lianos
{"title":"Blood-based biomarkers in gastric cancer peritoneal metastases: current evidence and potential clinical applications.","authors":"Gerasimia D Kyrochristou, Ilektra D Kyrochristou, Aikaterini Papameti, Fotios S Fousekis, Stefano Rausei, Konstantinos Vlachos, Georgios D Lianos","doi":"10.1080/17410541.2026.2754362","DOIUrl":"10.1080/17410541.2026.2754362","url":null,"abstract":"<p><p>Gastric cancer remains among the most common malignancies. Peritoneal metastases account for a significant share of mortality in gastric cancer; however, early detection is constrained by the limited sensitivity of current diagnostic approaches. Computed tomography represents the primary imaging modality for initial assessment, whereas staging laparoscopy, combined with peritoneal cytology and/or biopsy, plays a crucial role in detecting occult peritoneal metastases and confirming the diagnosis. The extent of peritoneal disease, the feasibility of complete cytoreduction, and the postoperative quality of life remain the primary requirements for deciding surgical intervention. As clinical staging and management remain challenging, non-invasive diagnostic and prognostic biomarkers are needed to improve risk stratification and optimize therapeutic strategies. This review summarizes the blood biomarkers reported during the last 5 years and their potential role in predicting peritoneal metastases. A literature search was conducted in PubMed on 12 March 2026, covering publications from March 2021 to March 2026. Ten eligible original studies were included. Although blood-based biomarkers show promise for improving the detection and management of peritoneal metastases in gastric cancer, the available evidence remains limited and heterogeneous. Further prospective, multicenter studies with external validation are required to establish their clinical utility before their integration into routine practice.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"503-512"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-29DOI: 10.1080/17410541.2026.2753757
Abazar Razavinia, Amir Razavinia, Mahsa Babaeizahraei, Faezeh Khanjanimoghtader, Forouzan Shahri, Navid Pourzardosht, Bahman Khalesi, Zahra Sadat Hashemi, Saeed Khalili
{"title":"Harnessing big data and artificial intelligence for personalized medicine: from multi-omics integration to clinical decision-making.","authors":"Abazar Razavinia, Amir Razavinia, Mahsa Babaeizahraei, Faezeh Khanjanimoghtader, Forouzan Shahri, Navid Pourzardosht, Bahman Khalesi, Zahra Sadat Hashemi, Saeed Khalili","doi":"10.1080/17410541.2026.2753757","DOIUrl":"10.1080/17410541.2026.2753757","url":null,"abstract":"<p><p>High-throughput technologies generate large and complex biological datasets that can challenge conventional methods of analysis and visualization. Artificial intelligence (AI) can support the analysis and integration of these datasets, provide new analytical approaches, and accelerate biological research. However, reliable AI applications depend on high-quality, consistent data. Technical errors, bias, and deficiencies in analytical methods can produce misleading findings and undermine reproducibility. AI-based approaches may help identify errors and improve data quality, but poor-quality or biased datasets, limited reproducibility, and concerns about privacy and ethics remain important barriers to their use in biological research. A literature search was performed in PubMed for papers published between 2015 and 2025. This review summarizes recent advances in AI for biological data analysis, including its main applications and potential benefits. It also discusses methodological, translational, and ethical challenges that may limit implementation. Particular attention is given to data quality and reliability, alongside the responsible use of AI in biological research and its translation to personalized medicine.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"487-501"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Personalized medicinePub Date : 2026-10-01Epub Date: 2026-10-29DOI: 10.1080/17410541.2026.2753738
Rita de Cássia Calderaro Coelho, Giovanna Gilioli da Costa Nunes, Kaio Evandro Cardoso Aguiar, Marianne Rodrigues Fernandes, Sidney Emanuel Batista Dos Santos, Ney Pereira Carneiro Dos Santos
{"title":"The role of <i>IL-17A, PRKAA1, PSCA</i> and <i>MIR196A2</i> genes in gastric cancer susceptibility: a Systematic review and meta-analysis.","authors":"Rita de Cássia Calderaro Coelho, Giovanna Gilioli da Costa Nunes, Kaio Evandro Cardoso Aguiar, Marianne Rodrigues Fernandes, Sidney Emanuel Batista Dos Santos, Ney Pereira Carneiro Dos Santos","doi":"10.1080/17410541.2026.2753738","DOIUrl":"10.1080/17410541.2026.2753738","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GCa) remains one of the most prevalent malignancies worldwide. Genetic variants in the <i>IL-17A</i>, <i>PRKAA1</i>, <i>PSCA</i>, and <i>MIR196A2</i> genes have been implicated in GCa susceptibility. The data were grouped from 10,353 cases and 10,260 controls. The heterogeneity between the studies was evaluated using the I<sup>2</sup> statistic, with values between 60% and 75%. The association between variants and the risk of GCa was evaluated by calculating the odds ratios (ORs) with confidence intervals (CIs) of 95%. Statistical significance was defined as <i>p</i> < 0.05.</p><p><strong>Areas covered: </strong>We evaluated 17 articles that identified genetic variants related to susceptibility to GCa and compiled the observed results through a meta-analysis. Our results revealed that variants were associated with the risk of developing GCa: <i>IL-17A</i> rs2275913 AA genotype (OR: 1.79; 95% CI: 1.53-2.09; <i>p</i> < 0.00001; I<sup>2</sup> = 14%), as well as <i>PSCA</i> rs2294008 CT (OR: 1.28; 95% CI: 1.12-1.47; <i>p</i> = 0.0003; I<sup>2</sup> = 0%) and CT/TT (OR: 1.32; 95% CI: 1.15-1.51; <i>p</i> < 0.0001; I<sup>2</sup> = 0%).</p><p><strong>Expert opinion/commentary: </strong>Our findings suggest that rs2275913 (<i>IL-17A</i>) and rs2294008 (<i>PSCA</i>) may be significant as susceptibility markers for GCa, potentially representing relevant candidates for future investigations.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"529-540"},"PeriodicalIF":0.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}